A COMPREHENSIVE REVIEW ON ANALYTICAL METHODS AND DRUG PROFILE OF ATOMOXETINE HYDROCHLORIDE AND OXYBUTYNIN CHLORIDE
Main Article Content
Keywords
Atomoxetine hydrochloride; Oxybutynin chloride; Analytical method development; RP-HPLC; HPTLC; Obstructive sleep apnea (OSA); Drug profile; Validation; Pharmacopeial methods.
Abstract
Atomoxetine hydrochloride, a selective norepinephrine reuptake inhibitor, and oxybutynin chloride, a muscarinic antagonist, have recently gained attention not only for their primary therapeutic applications—attention-deficit/hyperactivity disorder (ADHD) and overactive bladder, respectively—but also for their synergistic role in managing obstructive sleep apnea (OSA). This review provides a comprehensive overview of their physicochemical properties, mechanisms of action, and clinical relevance in OSA. In addition, it summarizes official pharmacopeial methods (IP, USP, BP) and reported analytical techniques, including HPLC, RP-HPLC, HPTLC, spectrophotometry, and micellar liquid chromatography, for the estimation of both drugs individually and in combination with other agents. Critical evaluation of chromatographic parameters, detection wavelengths, and mobile phases highlights the advancements and challenges in method development and validation. This review underlines the significance of robust, sensitive, and stability-indicating methods for routine quality control and pharmacokinetic studies, offering a consolidated reference for researchers and analysts working on atomoxetine and oxybutynin.
References
2. Kissinger PT. Instant Notes: Analytical Chemistry. Clin Chem. 2002; 48(12): 2303.
3. Sethi PD. HPLC-Quantitative analysis of pharmaceutical formulations; 3rd Edn; CBS publishers & distributors, 1997, pp 59-63.
4. Maspero C, Giannini L, Galbiati G, Rosso G, Farronato G. Obstructive sleep apnea syndrome: a literature review. Minerva Stomatol. 2015 Apr;64(2):97-109.
5. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet. 2014 Feb;383(9918):736-47. DOI: https://doi.org/10.1016/ S0140-6736(13)60734-5.
6. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013 May;177(9):1006-14.
7. Myers KA, Mrkobrada M, Simel DL. Does this patient have obstructive sleep apnea? The rational clinical examination systematic review. JAMA. 2013 Aug;310(7):731-41. DOI: https://doi.org/10.1001/ jama.2013.276185.
8. Med. 2019 Aug;7(8): 687-98. Medeiros CA, Bruin VM, Castro-Silva C, Araújo SMHA, Chaves Junior CM, Bruin PFC. Neck circumference, a bedside clinical feature related to mortality of acute ischemic stroke. Rev Assoc Med Bras (1992). 2011 Sep/Oct;57(5):559-64.
9. Ahbab S, Ataoğlu HE, Tuna M, Karasulu L, Çetin F, Temiz LU, et al. Neck circumference, metabolic syndrome and obstructive sleep apnea syndrome: evaluation of possible linkage. Med Sci Monit. 2013 Feb;19:111-7.
10. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation. 2005 Oct;112(17):2660.
11 Htoo AK, Greenberg H, Tongia S, Chen G, Henderson T, Wilson D, et al. Activation of nuclear factor kappa B in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath. 2006 Mar;10(1):43-50.
12. National Center for Biotechnology Information. PubChem Compound Summary for CID 54841, Atomoxetine Hydrochloride.https://pubchem.ncbi.nlm.nih.gov/compound/54841
13. National Center for Biotechnology Information. PubChem Compound Summary for CID 4636, Oxybutynin Hydrochloride. https://pubchem.ncbi.nlm.nih.gov/compound/4636
14. Indian Pharmacopoeia: Ministry of Health and Family Welfare Government of India, Ghaziabad, Vol. II, 2022: 1534-1535.
15. United States Pharmacopeial Convention. (2023). Atomoxetine Hydrochloride. In United States Pharmacopeia and National Formulary (USP 47–NF 42). Rockville, MD: U.S. Pharmacopeial Convention.
16. British Pharmacopoeia Commission. (2025). Atomoxetine Hydrochloride. In British Pharmacopoeia 2025 (Ph. Eur. 11.6 update). London: Medicines and Healthcare products Regulatory Agency (MHRA).
17. Faridi, N., Ghasemi, N., Qomi, M., & Ramezani, M. (2019). Prediction of the Trace Amounts of Atomoxetine in Biological Samples using optimized solvent bar microextraction technique coupled with HPLC-UV. Journal of Applied Chemical Research, 13(4), 28-41.
18. Ravisankar P. Development and validation of RP-HPLC method for the determination of atomoxetine capsules. IOSR J Pharm. 2019;9(5):16-27.
19. Rahman, Zubaidur, et al. “analytical method development and validation of atomoxetine hydrochloride using rapid high-performance liquid chromatographic technique”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 11, Nov. 2018, pp. 118-20.
20. Prajapati HR, Raveshiya PN, Jadav BB, Mahakal DM. Development and validation of high performance thin-layer chromatographic method for determination of atomoxetine hydrochloride in pharmaceutical dosage forms. Der Pharma Chemica. 2012;4(1).
21. Patel SK, Patel NJ. Development and validation of a stability-indicating RP-HPLC method for determination of atomoxetine hydrochloride in tablets. Journal of AOAC International. 2010 Jul 1;93(4):1207-14.
22. Gavin PF, Olsen BA. A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603). Journal of Pharmaceutical and Biomedical Analysis. 2008 Feb 13;46(3):431-41.
23. Anwar A Wassel, Heba El-agezy. Development and Validation of (HPLC) Method for Simultaneous Determination of Atomoxetine HCl & Fluoxetine HCl in their Pharmaceutical Dosage Forms. Biomed J Sci & Tech Res 34(4)-2021. BJSTR. MS.ID.005582.
24. Teichert J, Rowe JB, Ersche KD, Skandali N, Sacher J, Determination Aigner of A, Regenthal Atomoxetine R. or Escitalopram in human plasma by HPLC. Applications in Neuroscience Research Studies. International journal of clinical pharmacology and therapeutics. 2020 Aug 8;58(8):426.
25. García‐Ferrer, D., Peris‐Vicente, J., Bose, D., Durgbanshi, A., & Carda‐Broch, S. (2025). An Assay to Quantify Methylphenidate and Atomoxetine in Pharmaceutical Preparations by Micellar Liquid Chromatography. Separation Science Plus, 8(1), e202400302.
26. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2022. Vol. II. Ghaziabad: Indian Pharmacopoeia Commission; 2022: [3153-3154].
27. United States Pharmacopeial Convention. Oxybutynin Chloride Tablets. USP–NF. Rockville, MD: United States Pharmacopeial Convention; 2021.
28. British Pharmacopoeia Commission. Oxybutynin Hydrochloride. In: British Pharmacopoeia 2025. London: The Stationery Office; 2025. (Ph. Eur. monograph 1354).
29. Nataraj KS, Srinivasa Rao A, Aishwarya Lakshmi N, Naga Sravani G, Chinna Rao J.
Analytical Method Development and Validation for the Estimation of Related Substances in Oxybutynin HCl Prolonged Release Tablets by Reverse-Phase High-Performance Liquid Chromatography. International Journal of Pharmaceutical & Biological Archives (IJPBA). 2018; 9(2): 60–66. ISSN 2581-4303.
30. Mamatha J, Devanna N, Sandhya Rani J. Method Development and Validation of Oxybutynin Chloride by RP-HPLC Analytical Technique. International Journal of Advances in Science Engineering and Technology. 2017; 5(1): 125–130. ISSN 2321-9009.
31. Avula S, Babu NK, Ramana VM. Validated RP-HPLC method for the estimation of oxybutynin in formulation. Pharmacophore 2011;2:156–162.
32. Arma MVS, Kaushal AM, Garg S. Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin. J Pharm Biomed Anal 2004;36:669–674.
33. El-Gindy A. High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products. Farmaco. 2005 Aug;60(8):689-99.
34. Hassan, A. (2011). Simultaneous determination of selective drugs, fluoxetine, ketoprofen, oxybutynin and clonidine in human plasma. Jordan Journal of Pharmaceutical Sciences, 4(2), 114–123.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Soham B Joshi
Khyati College of Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.
Ms.Purvi Ramanuj
Department of QA and Pharmaceutical Chemistry, Khyati College of Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.
Dr.Pragnesh Patani
Principal, Khyati College of Pharmacy, Gujarat Technological University, Ahmedabad, Gujarat, India.